Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of Bempedoic acid on cardiovascular events in patients with statin intolerance.

[1]  Lawrence A Leiter,et al.  Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. , 2019, JAMA.

[2]  A. D'Angelo,et al.  Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study , 2019, Drug design, development and therapy.

[3]  Lawrence A Leiter,et al.  Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy , 2019, European journal of preventive cardiology.

[4]  N. Lalwani,et al.  Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. , 2019, Journal of clinical lipidology.

[5]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[6]  D. Gaudet,et al.  Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance , 2019, Journal of the American Heart Association.

[7]  C. Ballantyne,et al.  Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol , 2019, The New England journal of medicine.

[8]  J. Danesh,et al.  Mendelian Randomization Study of ACLY and Cardiovascular Disease , 2019, The New England journal of medicine.

[9]  Deepak L. Bhatt,et al.  Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease , 2019, JAMA.

[10]  K. Khunti,et al.  Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe. , 2018, JAMA network open.

[11]  Lawrence A Leiter,et al.  Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. , 2018, Atherosclerosis.

[12]  P. Thompson,et al.  Statin-Associated Muscle Disease: Advances in Diagnosis and Management , 2018, Neurotherapeutics.

[13]  D. Panagiotakos,et al.  The Role of Nutraceuticals in Statin Intolerant Patients. , 2018, Journal of the American College of Cardiology.

[14]  R. Ofori-Asenso,et al.  Reinitiation of Statin Therapy After Discontinuation: A Meta‐analysis , 2018, Mayo Clinic proceedings.

[15]  J. Pickering,et al.  Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient (LDLR+/− and LDLR−/−) Yucatan Miniature Pigs , 2018, Arteriosclerosis, thrombosis, and vascular biology.

[16]  M. Banach,et al.  Optimizing Cholesterol Treatment in Patients With Muscle Complaints. , 2017, Journal of the American College of Cardiology.

[17]  Lale Tokgözoğlu,et al.  Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel , 2017, European heart journal.

[18]  Stephen L. Pinkosky,et al.  Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr−/− Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid , 2017, Arteriosclerosis, thrombosis, and vascular biology.

[19]  Robert J Sanchez,et al.  The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability , 2017, Cardiovascular Drugs and Therapy.

[20]  Stephen L. Pinkosky,et al.  Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis , 2016, Nature Communications.

[21]  J. Mckenney,et al.  Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy. , 2016, The American journal of cardiology.

[22]  C. Ballantyne,et al.  Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. , 2016, JAMA.

[23]  Improve-It Investigators Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[24]  P. Thompson,et al.  Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. , 2015, Journal of clinical lipidology.

[25]  M. Banach,et al.  Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel , 2015, Expert opinion on drug safety.

[26]  C. Glueck,et al.  Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation , 2015, North American journal of medical sciences.

[27]  Lawrence A Leiter,et al.  Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.

[28]  D. Waters,et al.  Risk of new-onset diabetes and cardiovascular risk reduction from high-dose statin therapy in pre-diabetics and non-pre-diabetics: an analysis from TNT and IDEAL. , 2015, Journal of the American College of Cardiology.

[29]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[30]  M. Milad,et al.  Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus , 2014, Arteriosclerosis, thrombosis, and vascular biology.

[31]  C. Ballantyne,et al.  Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. , 2013, Journal of the American College of Cardiology.

[32]  S. Hazen,et al.  Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. , 2013, American heart journal.

[33]  R. Lister,et al.  ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK , 2013, Journal of Lipid Research.

[34]  Khosrow Adeli,et al.  AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism[S] , 2013, Journal of Lipid Research.

[35]  K. Thakker,et al.  Prevalence of Dyslipidemia and Lipid Goal Attainment in Statin-Treated Subjects From 3 Data Sources: A Retrospective Analysis , 2012, Journal of the American Heart Association.

[36]  P. Libby,et al.  Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial , 2012, The Lancet.

[37]  M. Gnant,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010 .

[38]  R. Collins,et al.  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.

[39]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[40]  P. Thompson,et al.  Effectiveness and Tolerability of Every-Other-Day Rosuvastatin Dosing in Patients with Prior Statin Intolerance , 2008, The Annals of pharmacotherapy.

[41]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[42]  Peter Libby,et al.  The forgotten majority: unfinished business in cardiovascular risk reduction. , 2005, Journal of the American College of Cardiology.

[43]  M. Pape,et al.  Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome Published, JLR Papers in Press, April 21, 2004. DOI 10.1194/jlr.M400018-JLR200 , 2004, Journal of Lipid Research.